STOCK TITAN

[8-K] Kairos Pharma, Ltd. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is offering unsecured medium-term senior buffer securities linked to the S&P 500® Index. The notes will be issued on 5 Aug 2025, mature on 5 Aug 2027, and are sold in $1,000 denominations.

Key economics: (1) Upside participation 200% of any positive index move, capped by a maximum return set on pricing (≥ 16.75%, or ≥ $167.50 per note). (2) Downside buffer: first 10% index decline is protected; losses beyond 10% are passed through point-for-point. (3) No coupons, no dividends, no early call.

Initial valuation: Citigroup expects the estimated value on the pricing date to be at least $915.50 (≈ 91.6% of issue price) due to embedded costs and its internal funding rate. Underwriting fee is up to $22.50 (2.25%) per note; proceeds to issuer at least $977.50.

Liquidity & credit: Notes will not be listed; any secondary market will be made solely by CGMI on a best-efforts basis and may be discontinued. All payments are subject to the senior unsecured credit risk of both the issuer and Citigroup Inc.

Risk highlights (excerpt of PS-4 & PS-5): potential for significant principal loss, limited upside versus direct equity exposure, valuation and market-making conflicts, and uncertain U.S. tax treatment (pre-paid forward contract assumption; Section 871(m) analysis pending).

Investor profile: suitable only for investors who (i) seek 2-year exposure to the S&P 500 with a 10% buffer, (ii) can tolerate capped gains and amplified downside after the buffer, (iii) are comfortable with illiquidity and issuer credit risk, and (iv) do not require current income.

Citigroup Global Markets Holdings Inc., garantita da Citigroup Inc., offre titoli senior buffer unsecured a medio termine collegati all'indice S&P 500®. Le obbligazioni saranno emesse il 5 agosto 2025, scadranno il 5 agosto 2027 e sono vendute in tagli da $1.000.

Principali caratteristiche economiche: (1) Partecipazione al rialzo del 200% su qualsiasi movimento positivo dell'indice, con un rendimento massimo stabilito in fase di prezzo (≥ 16,75%, ovvero ≥ $167,50 per obbligazione). (2) Buffer al ribasso: il primo 10% di ribasso dell'indice è protetto; le perdite oltre il 10% sono trasferite punto per punto. (3) Nessuna cedola, nessun dividendo, nessuna possibilità di richiamo anticipato.

Valutazione iniziale: Citigroup prevede che il valore stimato alla data di prezzo sia almeno $915,50 (circa il 91,6% del prezzo di emissione) a causa dei costi impliciti e del proprio tasso di finanziamento interno. La commissione di sottoscrizione può arrivare fino a $22,50 (2,25%) per obbligazione; i proventi per l’emittente saranno almeno $977,50.

Liquidità e rischio di credito: Le obbligazioni non saranno quotate; il mercato secondario sarà offerto esclusivamente da CGMI con sforzi ragionevoli e potrà essere interrotto. Tutti i pagamenti sono soggetti al rischio di credito senior unsecured sia dell’emittente che di Citigroup Inc.

Rischi principali (estratto da PS-4 & PS-5): possibile perdita significativa del capitale, guadagni limitati rispetto all’esposizione diretta azionaria, conflitti di valutazione e market making, trattamento fiscale USA incerto (assunzione di contratto forward prepagato; analisi in corso secondo la Sezione 871(m)).

Profilo dell’investitore: adatto solo a investitori che (i) cercano un’esposizione biennale all’S&P 500 con un buffer del 10%, (ii) tollerano guadagni limitati e perdite amplificate oltre il buffer, (iii) sono a proprio agio con illiquidità e rischio di credito dell’emittente, e (iv) non necessitano di reddito corrente.

Citigroup Global Markets Holdings Inc., garantizado por Citigroup Inc., ofrece valores senior buffer no garantizados a medio plazo vinculados al índice S&P 500®. Los bonos se emitirán el 5 de agosto 2025, vencen el 5 de agosto 2027 y se venden en denominaciones de $1,000.

Aspectos económicos clave: (1) Participación al alza del 200% sobre cualquier movimiento positivo del índice, con un rendimiento máximo establecido en la fijación del precio (≥ 16.75%, o ≥ $167.50 por bono). (2) Buffer a la baja: la primera caída del índice del 10% está protegida; las pérdidas que excedan el 10% se transfieren punto por punto. (3) Sin cupones, sin dividendos, sin llamada anticipada.

Valoración inicial: Citigroup espera que el valor estimado en la fecha de fijación de precio sea al menos $915.50 (aprox. 91.6% del precio de emisión) debido a costos incorporados y su tasa interna de financiación. La comisión de suscripción es hasta $22.50 (2.25%) por bono; los ingresos para el emisor serán al menos $977.50.

Liquidez y crédito: Los bonos no estarán listados; cualquier mercado secundario será proporcionado únicamente por CGMI bajo un esfuerzo razonable y puede ser discontinuado. Todos los pagos están sujetos al riesgo crediticio senior no garantizado tanto del emisor como de Citigroup Inc.

Aspectos destacados de riesgo (extracto de PS-4 & PS-5): posibilidad de pérdida significativa de capital, ganancias limitadas en comparación con la exposición directa a acciones, conflictos de valoración y creación de mercado, y tratamiento fiscal estadounidense incierto (suposición de contrato forward prepagado; análisis pendiente bajo la Sección 871(m)).

Perfil del inversor: adecuado solo para inversores que (i) buscan exposición de 2 años al S&P 500 con un buffer del 10%, (ii) pueden tolerar ganancias limitadas y pérdidas amplificadas después del buffer, (iii) están cómodos con la iliquidez y el riesgo crediticio del emisor, y (iv) no requieren ingresos actuales.

Citigroup Global Markets Holdings Inc.는 Citigroup Inc.가 보증하는 무담보 중기 선순위 버퍼 증권을 S&P 500® 지수에 연동하여 제공합니다. 해당 노트는 2025년 8월 5일에 발행되며, 2027년 8월 5일에 만기되고, $1,000 단위로 판매됩니다.

주요 경제 조건: (1) 지수 상승 시 200%의 상승 참여율, 가격 책정 시 정해진 최대 수익률상한 설정(≥ 16.75%, 즉 노트당 ≥ $167.50). (2) 하락 버퍼: 최초 10% 지수 하락은 보호되며, 10% 초과 손실은 1:1로 반영. (3) 쿠폰 없음, 배당 없음, 조기 상환 없음.

초기 평가: Citigroup은 가격 책정일에 내재 비용과 내부 자금 조달률로 인해 추정 가치가 최소 $915.50(발행가의 약 91.6%)가 될 것으로 예상합니다. 인수 수수료는 노트당 최대 $22.50(2.25%)이며, 발행자에게 돌아가는 수익은 최소 $977.50입니다.

유동성 및 신용: 노트는 상장되지 않으며, 2차 시장은 CGMI가 최선의 노력을 다해 제공하며 중단될 수 있습니다. 모든 지급은 발행자 및 Citigroup Inc.의 선순위 무담보 신용 위험에 따릅니다.

위험 요약 (PS-4 및 PS-5 발췌): 원금 손실 가능성, 직접 주식 노출 대비 제한된 상승 잠재력, 평가 및 시장 조성 갈등, 불확실한 미국 세무 처리(선불 선도 계약 가정; 섹션 871(m) 분석 진행 중).

투자자 프로필: (i) 10% 버퍼가 있는 S&P 500에 2년간 노출되길 원하는 투자자, (ii) 버퍼 이후 제한된 상승과 확대된 하락을 감내할 수 있는 투자자, (iii) 유동성 부족과 발행자 신용 위험을 수용할 수 있는 투자자, (iv) 현재 소득이 필요 없는 투자자에게 적합합니다.

Citigroup Global Markets Holdings Inc., garantie par Citigroup Inc., propose des titres senior buffer à moyen terme non garantis liés à l’indice S&P 500®. Les notes seront émises le 5 août 2025, arriveront à échéance le 5 août 2027 et sont vendues par coupures de 1 000 $.

Éléments économiques clés : (1) Participation à la hausse de 200 % sur toute hausse positive de l’indice, plafonnée par un rendement maximal fixé lors de la tarification (≥ 16,75 %, soit ≥ 167,50 $ par note). (2) Buffer à la baisse : la première baisse de 10 % de l’indice est protégée ; les pertes au-delà de 10 % sont transmises point par point. (3) Pas de coupons, pas de dividendes, pas de remboursement anticipé.

Évaluation initiale : Citigroup prévoit que la valeur estimée à la date de tarification sera au moins de 915,50 $ (environ 91,6 % du prix d’émission) en raison des coûts intégrés et de son taux de financement interne. Les frais de souscription peuvent atteindre 22,50 $ (2,25 %) par note ; les produits pour l’émetteur seront d’au moins 977,50 $.

Liquidité et crédit : Les notes ne seront pas cotées ; tout marché secondaire sera assuré uniquement par CGMI sur une base de meilleurs efforts et pourra être interrompu. Tous les paiements sont soumis au risque de crédit senior non garanti de l’émetteur et de Citigroup Inc.

Points clés de risque (extrait des PS-4 & PS-5) : risque important de perte en capital, potentiel de hausse limité comparé à une exposition directe aux actions, conflits d’évaluation et de tenue de marché, traitement fiscal américain incertain (hypothèse de contrat forward prépayé ; analyse en cours selon la Section 871(m)).

Profil investisseur : adapté uniquement aux investisseurs qui (i) recherchent une exposition de 2 ans au S&P 500 avec un buffer de 10 %, (ii) peuvent tolérer des gains plafonnés et des pertes amplifiées après le buffer, (iii) sont à l’aise avec l’illiquidité et le risque de crédit de l’émetteur, et (iv) ne nécessitent pas de revenu courant.

Citigroup Global Markets Holdings Inc., garantiert durch Citigroup Inc., bietet unbesicherte mittel- bis langfristige Senior-Buffer-Wertpapiere mit Bezug zum S&P 500®-Index an. Die Notes werden am 5. August 2025 ausgegeben, laufen bis zum 5. August 2027 und werden in Stückelungen von $1.000 verkauft.

Wesentliche wirtschaftliche Merkmale: (1) Aufwärtsbeteiligung von 200% an jeglicher positiver Indexbewegung, begrenzt durch eine bei der Preisfestsetzung festgelegte maximale Rendite (≥ 16,75%, bzw. ≥ $167,50 pro Note). (2) Abwärts-Puffer: Die ersten 10% Indexverlust sind geschützt; Verluste darüber hinaus werden Punkt für Punkt weitergegeben. (3) Keine Kupons, keine Dividenden, kein vorzeitiger Rückruf.

Erstbewertung: Citigroup erwartet, dass der geschätzte Wert am Preisfestsetzungstag mindestens $915,50 (ca. 91,6% des Ausgabepreises) beträgt, bedingt durch eingebaute Kosten und die interne Finanzierungsrate. Die Underwriting-Gebühr beträgt bis zu $22,50 (2,25%) pro Note; Erlöse für den Emittenten mindestens $977,50.

Liquidität & Kredit: Die Notes werden nicht börsennotiert sein; ein Sekundärmarkt wird ausschließlich von CGMI auf Best-Effort-Basis bereitgestellt und kann eingestellt werden. Alle Zahlungen unterliegen dem unbesicherten Senior-Kreditrisiko des Emittenten und von Citigroup Inc.

Risikohighlights (Auszug aus PS-4 & PS-5): Potenziell erheblicher Kapitalverlust, begrenzte Aufwärtschancen im Vergleich zur direkten Aktienexponierung, Bewertungs- und Market-Making-Konflikte sowie unsichere US-Steuerbehandlung (Annahme eines vorausbezahlten Forward-Vertrags; Analyse nach Abschnitt 871(m) läuft).

Investorprofil: Geeignet nur für Anleger, die (i) eine 2-jährige Exponierung zum S&P 500 mit 10% Puffer suchen, (ii) begrenzte Gewinne und verstärkte Verluste nach dem Puffer tolerieren können, (iii) mit Illiquidität und Emittenten-Kreditrisiko umgehen können und (iv) kein laufendes Einkommen benötigen.

Positive
  • 10% downside buffer provides limited protection against moderate S&P 500 declines.
  • 200% upside participation allows leveraged exposure to modest index gains.
  • Citigroup Inc. guarantee elevates credit standing relative to standalone issuer risk.
Negative
  • Maximum return capped at ≥16.75%, severely limiting upside versus direct equity exposure.
  • No interest or dividends; total return relies solely on index movement at maturity.
  • Estimated value (~$915.50) is well below issue price, reflecting embedded fees and funding spread.
  • Illiquidity risk: notes are unlisted and secondary market making is discretionary.
  • Principal loss beyond 10% buffer is dollar-for-dollar with index decline.
  • Uncertain tax treatment—classification as prepaid forward may be challenged.

Insights

TL;DR: 2-year S&P 500 note with 10% buffer, 200% leverage to gains up to ~16.75%; unsecured, illiquid, fee-laden.

The terms conform to typical U.S. retail buffer structures. A 200% participation rate sounds attractive, but the low ≥16.75% cap truncates upside quickly: index appreciation above 8.375% yields no incremental benefit. Investors effectively pay a 2.25% placement fee plus an immediate ≈8.5% economic discount versus issue price, limiting secondary-market exit potential. Credit exposure to Citigroup is senior but still subordinate to deposit obligations. Relative to an at-the-money 2-year S&P call spread, the risk-reward skew is modest; the 10% buffer may appeal to cautious equity investors, yet the structure underperforms direct equity ownership in most upward scenarios and all dividend scenarios. Overall impact to Citi is immaterial; for investors, utility depends on specific market views and risk tolerance.

TL;DR: Note offers downside protection but embeds valuation, liquidity, tax and credit risks that can erode returns.

The absence of interim cash flows, potential principal loss beyond 10%, and unlisted status raise material risk. The internal funding rate and bid-ask spread mean investors realize an immediate mark-to-market gap of roughly 8-10% versus par. Credit risk is two-layered (issuer and guarantor). Tax treatment as a prepaid forward is untested; adverse IRS rulings could impose ordinary income or withholding. These factors skew the instrument toward riskier retail investors, not institutions. I classify the note as not impactful from a systemic view but negative for unsophisticated buyers expecting full principal protection.

Citigroup Global Markets Holdings Inc., garantita da Citigroup Inc., offre titoli senior buffer unsecured a medio termine collegati all'indice S&P 500®. Le obbligazioni saranno emesse il 5 agosto 2025, scadranno il 5 agosto 2027 e sono vendute in tagli da $1.000.

Principali caratteristiche economiche: (1) Partecipazione al rialzo del 200% su qualsiasi movimento positivo dell'indice, con un rendimento massimo stabilito in fase di prezzo (≥ 16,75%, ovvero ≥ $167,50 per obbligazione). (2) Buffer al ribasso: il primo 10% di ribasso dell'indice è protetto; le perdite oltre il 10% sono trasferite punto per punto. (3) Nessuna cedola, nessun dividendo, nessuna possibilità di richiamo anticipato.

Valutazione iniziale: Citigroup prevede che il valore stimato alla data di prezzo sia almeno $915,50 (circa il 91,6% del prezzo di emissione) a causa dei costi impliciti e del proprio tasso di finanziamento interno. La commissione di sottoscrizione può arrivare fino a $22,50 (2,25%) per obbligazione; i proventi per l’emittente saranno almeno $977,50.

Liquidità e rischio di credito: Le obbligazioni non saranno quotate; il mercato secondario sarà offerto esclusivamente da CGMI con sforzi ragionevoli e potrà essere interrotto. Tutti i pagamenti sono soggetti al rischio di credito senior unsecured sia dell’emittente che di Citigroup Inc.

Rischi principali (estratto da PS-4 & PS-5): possibile perdita significativa del capitale, guadagni limitati rispetto all’esposizione diretta azionaria, conflitti di valutazione e market making, trattamento fiscale USA incerto (assunzione di contratto forward prepagato; analisi in corso secondo la Sezione 871(m)).

Profilo dell’investitore: adatto solo a investitori che (i) cercano un’esposizione biennale all’S&P 500 con un buffer del 10%, (ii) tollerano guadagni limitati e perdite amplificate oltre il buffer, (iii) sono a proprio agio con illiquidità e rischio di credito dell’emittente, e (iv) non necessitano di reddito corrente.

Citigroup Global Markets Holdings Inc., garantizado por Citigroup Inc., ofrece valores senior buffer no garantizados a medio plazo vinculados al índice S&P 500®. Los bonos se emitirán el 5 de agosto 2025, vencen el 5 de agosto 2027 y se venden en denominaciones de $1,000.

Aspectos económicos clave: (1) Participación al alza del 200% sobre cualquier movimiento positivo del índice, con un rendimiento máximo establecido en la fijación del precio (≥ 16.75%, o ≥ $167.50 por bono). (2) Buffer a la baja: la primera caída del índice del 10% está protegida; las pérdidas que excedan el 10% se transfieren punto por punto. (3) Sin cupones, sin dividendos, sin llamada anticipada.

Valoración inicial: Citigroup espera que el valor estimado en la fecha de fijación de precio sea al menos $915.50 (aprox. 91.6% del precio de emisión) debido a costos incorporados y su tasa interna de financiación. La comisión de suscripción es hasta $22.50 (2.25%) por bono; los ingresos para el emisor serán al menos $977.50.

Liquidez y crédito: Los bonos no estarán listados; cualquier mercado secundario será proporcionado únicamente por CGMI bajo un esfuerzo razonable y puede ser discontinuado. Todos los pagos están sujetos al riesgo crediticio senior no garantizado tanto del emisor como de Citigroup Inc.

Aspectos destacados de riesgo (extracto de PS-4 & PS-5): posibilidad de pérdida significativa de capital, ganancias limitadas en comparación con la exposición directa a acciones, conflictos de valoración y creación de mercado, y tratamiento fiscal estadounidense incierto (suposición de contrato forward prepagado; análisis pendiente bajo la Sección 871(m)).

Perfil del inversor: adecuado solo para inversores que (i) buscan exposición de 2 años al S&P 500 con un buffer del 10%, (ii) pueden tolerar ganancias limitadas y pérdidas amplificadas después del buffer, (iii) están cómodos con la iliquidez y el riesgo crediticio del emisor, y (iv) no requieren ingresos actuales.

Citigroup Global Markets Holdings Inc.는 Citigroup Inc.가 보증하는 무담보 중기 선순위 버퍼 증권을 S&P 500® 지수에 연동하여 제공합니다. 해당 노트는 2025년 8월 5일에 발행되며, 2027년 8월 5일에 만기되고, $1,000 단위로 판매됩니다.

주요 경제 조건: (1) 지수 상승 시 200%의 상승 참여율, 가격 책정 시 정해진 최대 수익률상한 설정(≥ 16.75%, 즉 노트당 ≥ $167.50). (2) 하락 버퍼: 최초 10% 지수 하락은 보호되며, 10% 초과 손실은 1:1로 반영. (3) 쿠폰 없음, 배당 없음, 조기 상환 없음.

초기 평가: Citigroup은 가격 책정일에 내재 비용과 내부 자금 조달률로 인해 추정 가치가 최소 $915.50(발행가의 약 91.6%)가 될 것으로 예상합니다. 인수 수수료는 노트당 최대 $22.50(2.25%)이며, 발행자에게 돌아가는 수익은 최소 $977.50입니다.

유동성 및 신용: 노트는 상장되지 않으며, 2차 시장은 CGMI가 최선의 노력을 다해 제공하며 중단될 수 있습니다. 모든 지급은 발행자 및 Citigroup Inc.의 선순위 무담보 신용 위험에 따릅니다.

위험 요약 (PS-4 및 PS-5 발췌): 원금 손실 가능성, 직접 주식 노출 대비 제한된 상승 잠재력, 평가 및 시장 조성 갈등, 불확실한 미국 세무 처리(선불 선도 계약 가정; 섹션 871(m) 분석 진행 중).

투자자 프로필: (i) 10% 버퍼가 있는 S&P 500에 2년간 노출되길 원하는 투자자, (ii) 버퍼 이후 제한된 상승과 확대된 하락을 감내할 수 있는 투자자, (iii) 유동성 부족과 발행자 신용 위험을 수용할 수 있는 투자자, (iv) 현재 소득이 필요 없는 투자자에게 적합합니다.

Citigroup Global Markets Holdings Inc., garantie par Citigroup Inc., propose des titres senior buffer à moyen terme non garantis liés à l’indice S&P 500®. Les notes seront émises le 5 août 2025, arriveront à échéance le 5 août 2027 et sont vendues par coupures de 1 000 $.

Éléments économiques clés : (1) Participation à la hausse de 200 % sur toute hausse positive de l’indice, plafonnée par un rendement maximal fixé lors de la tarification (≥ 16,75 %, soit ≥ 167,50 $ par note). (2) Buffer à la baisse : la première baisse de 10 % de l’indice est protégée ; les pertes au-delà de 10 % sont transmises point par point. (3) Pas de coupons, pas de dividendes, pas de remboursement anticipé.

Évaluation initiale : Citigroup prévoit que la valeur estimée à la date de tarification sera au moins de 915,50 $ (environ 91,6 % du prix d’émission) en raison des coûts intégrés et de son taux de financement interne. Les frais de souscription peuvent atteindre 22,50 $ (2,25 %) par note ; les produits pour l’émetteur seront d’au moins 977,50 $.

Liquidité et crédit : Les notes ne seront pas cotées ; tout marché secondaire sera assuré uniquement par CGMI sur une base de meilleurs efforts et pourra être interrompu. Tous les paiements sont soumis au risque de crédit senior non garanti de l’émetteur et de Citigroup Inc.

Points clés de risque (extrait des PS-4 & PS-5) : risque important de perte en capital, potentiel de hausse limité comparé à une exposition directe aux actions, conflits d’évaluation et de tenue de marché, traitement fiscal américain incertain (hypothèse de contrat forward prépayé ; analyse en cours selon la Section 871(m)).

Profil investisseur : adapté uniquement aux investisseurs qui (i) recherchent une exposition de 2 ans au S&P 500 avec un buffer de 10 %, (ii) peuvent tolérer des gains plafonnés et des pertes amplifiées après le buffer, (iii) sont à l’aise avec l’illiquidité et le risque de crédit de l’émetteur, et (iv) ne nécessitent pas de revenu courant.

Citigroup Global Markets Holdings Inc., garantiert durch Citigroup Inc., bietet unbesicherte mittel- bis langfristige Senior-Buffer-Wertpapiere mit Bezug zum S&P 500®-Index an. Die Notes werden am 5. August 2025 ausgegeben, laufen bis zum 5. August 2027 und werden in Stückelungen von $1.000 verkauft.

Wesentliche wirtschaftliche Merkmale: (1) Aufwärtsbeteiligung von 200% an jeglicher positiver Indexbewegung, begrenzt durch eine bei der Preisfestsetzung festgelegte maximale Rendite (≥ 16,75%, bzw. ≥ $167,50 pro Note). (2) Abwärts-Puffer: Die ersten 10% Indexverlust sind geschützt; Verluste darüber hinaus werden Punkt für Punkt weitergegeben. (3) Keine Kupons, keine Dividenden, kein vorzeitiger Rückruf.

Erstbewertung: Citigroup erwartet, dass der geschätzte Wert am Preisfestsetzungstag mindestens $915,50 (ca. 91,6% des Ausgabepreises) beträgt, bedingt durch eingebaute Kosten und die interne Finanzierungsrate. Die Underwriting-Gebühr beträgt bis zu $22,50 (2,25%) pro Note; Erlöse für den Emittenten mindestens $977,50.

Liquidität & Kredit: Die Notes werden nicht börsennotiert sein; ein Sekundärmarkt wird ausschließlich von CGMI auf Best-Effort-Basis bereitgestellt und kann eingestellt werden. Alle Zahlungen unterliegen dem unbesicherten Senior-Kreditrisiko des Emittenten und von Citigroup Inc.

Risikohighlights (Auszug aus PS-4 & PS-5): Potenziell erheblicher Kapitalverlust, begrenzte Aufwärtschancen im Vergleich zur direkten Aktienexponierung, Bewertungs- und Market-Making-Konflikte sowie unsichere US-Steuerbehandlung (Annahme eines vorausbezahlten Forward-Vertrags; Analyse nach Abschnitt 871(m) läuft).

Investorprofil: Geeignet nur für Anleger, die (i) eine 2-jährige Exponierung zum S&P 500 mit 10% Puffer suchen, (ii) begrenzte Gewinne und verstärkte Verluste nach dem Puffer tolerieren können, (iii) mit Illiquidität und Emittenten-Kreditrisiko umgehen können und (iv) kein laufendes Einkommen benötigen.

false 0001962011 0001962011 2025-07-15 2025-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 15, 2025

 

Kairos Pharma, Ltd.

(Exact name of registrant as specified in its charter)

 

Delaware   001-42275   46-2993314

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2355 Westwood Blvd., #139

Los Angeles CA 90064

(Address of principal executive offices) (Zip Code)

 

(310) 948-2356

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol (s)   Name of each exchange on which registered
Common Stock, par value $0.001, per share   KAPA   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 8.01. Other Events.

 

On July 15, 2025, Kairos Pharma, Ltd., a Delaware corporation (the “Company”), issued a press release announcing positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim safety analysis of the trial demonstrated that ENV-105, a first-in-class CD105 antagonist, was well tolerated when combined with standard of care hormone therapy, apalutamide, from the first ten enrolled patients. Thus far, there have been no dose-limiting toxicities or unexpected adverse events reported to date. In addition, the treatment-related side effects were manageable with standard supportive care. Notably, no Grade 3 or 4 toxicities were observed.

 

A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information included in this Item 8.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 8.01, including Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

  Description
     
99.1   Press Release dated July 15, 2025
104   Cover Page Interactive Data File (embedded within Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 15, 2025 KAIROS PHARMA, LTD.
     
  By: /s/ John S. Yu
    John S. Yu
    Chief Executive Officer

 

 

 

 

FAQ

What is the maturity date of Citigroup's S&P 500 buffer securities (C)?

The notes mature on August 5, 2027.

How much upside can investors earn on the Citigroup buffer notes?

Gains are leveraged at 200% but capped by a maximum return of at least 16.75% ($167.50) per $1,000 note.

How does the 10% buffer work on these Citigroup structured notes?

If the S&P 500 falls ≤10% from the initial level, investors receive their full principal; losses beyond the 10% buffer reduce principal 1-for-1.

Do the Citigroup buffer securities pay interest or dividends?

No. The notes pay no coupons and pass through no S&P 500 dividends during the two-year term.

Will I be able to sell the Citigroup buffer notes before maturity?

The notes are not exchange-listed; CGMI may provide a secondary market but can suspend it at any time, so liquidity is uncertain.

What is the estimated initial value versus the $1,000 issue price?

Citigroup estimates the value at ≥ $915.50, about 8–9% below par, due to fees and funding costs.
KAIROS PHARMA LTD

NYSE:KAPA

KAPA Rankings

KAPA Latest News

KAPA Stock Data

12.38M
8.89M
64.8%
2.97%
0.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
LOS ANGELES